RxDoctor Payments Data

Eric Bandy, MD

Internal Medicine · Powderly, KYNPI 1881695815

Payments from drug & device makers

$1,785in general payments, 2019–2025

Across 112 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$584
  • Pfizer$179
  • Lilly USA, LLC$159
  • Bayer$147
  • Amarin Pharma, Inc.$120
  • Astellas Pharma US Inc$109
  • plus $488 from 16 others

What the payments were for

  • Food & beverage$1,68594%
  • Education$1006%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,785 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$28,038
Medicare patients
269
Services billed
2,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide220$265,895
JardianceEmpagliflozin140$121,714
EliquisApixaban104$103,526
FarxigaDapagliflozin Propanediol69$71,101
MounjaroTirzepatide57$70,553
JanuviaSitagliptin Phosphate54$43,928
TrulicityDulaglutide19$33,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$26,658
MyrbetriqMirabegron32$23,166
XareltoRivaroxaban20$18,408
LinzessLinaclotide16$10,237
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,280
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$8,205
Breo ElliptaFluticasone/Vilanterol18$7,159
Combivent RespimatIpratropium/Albuterol Sulfate15$6,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$584$265,895220 claims
Boehringer IngelheimJardiance, Combivent Respimat$14$128,643155 claims
Lilly USA, LLCMounjaro, Trulicity$159$104,42776 claims
PfizerEliquis$179$103,526104 claims
AstraZenecaFarxiga$105$71,10169 claims
Astellas Pharma US IncMyrbetriq$109$23,16632 claims
AbbVieLinzess$29$10,23716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Powderly

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →